Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 656,002
  • Shares Outstanding, K 45,461
  • Annual Sales, $ 82,460 K
  • Annual Income, $ -81,070 K
  • 60-Month Beta 2.37
  • Price/Sales 7.47
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade CLLS with:

Options Overview

Details
  • Implied Volatility 74.51%
  • Historical Volatility 57.42%
  • IV Percentile 6%
  • IV Rank 23.95%
  • IV High 113.06% on 02/23/21
  • IV Low 62.37% on 09/18/20
  • Put/Call Vol Ratio 0.36
  • Today's Volume 87
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 271
  • Open Int (30-Day) 410

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.83
  • Number of Estimates 3
  • High Estimate -0.57
  • Low Estimate -0.99
  • Prior Year -0.71
  • Growth Rate Est. (year over year) -16.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.88 +21.46%
on 08/19/21
15.50 -6.90%
on 09/02/21
+2.10 (+17.03%)
since 08/17/21
3-Month
11.88 +21.46%
on 08/19/21
16.45 -12.28%
on 06/28/21
-0.69 (-4.56%)
since 06/17/21
52-Week
11.88 +21.46%
on 08/19/21
34.71 -58.43%
on 01/20/21
-5.92 (-29.09%)
since 09/17/20

Most Recent Stories

More News
Cellectis Announces Participation in Five Investor Conferences

Cellectis S.A. (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells...

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

MRK : 71.68 (-0.40%)
RGEN : 306.90 (+2.34%)
CLLS : 14.43 (+6.49%)
IOVA : 25.47 (+8.15%)
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

? Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

Cellectis S.A. (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells...

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag

Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.

BAYRY : 13.2900 (-1.41%)
CLLS : 14.43 (+6.49%)
ALLO : 25.38 (+3.55%)
BNTX : 359.18 (-3.61%)
Cellectis' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

? Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for...

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021

Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS - Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

Cellectis S.A. (NASDAQ: CLLS - Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic...

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021

-- Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical...

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)
Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

CMVLF : 14.1800 (+9.08%)
CLLS : 14.43 (+6.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 15.57
2nd Resistance Point 15.03
1st Resistance Point 14.73
Last Price 14.43
1st Support Level 13.89
2nd Support Level 13.35
3rd Support Level 13.05

See More

52-Week High 34.71
Fibonacci 61.8% 25.99
Fibonacci 50% 23.30
Fibonacci 38.2% 20.60
Last Price 14.43
52-Week Low 11.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar